Codiak BioSciences
500 Technology Square
Cambridge
Massachusetts
02139
United States
Website: http://www.codiakbio.com/
Email: info@codiakbio.com
About Codiak BioSciences
Codiak BioSciences is developing a broad platform for the delivery of macromolecules to the cytoplasm of diverse cells and tissues, to create a proprietary pipeline of novel, targeted medicines for diseases with high unmet medical need. - See more at: http://www.codiakbio.com/science/
93 articles about Codiak BioSciences
-
A summary of IPOs from companies in the biotech and pharma world since April 1, 2019.
-
Development of the engExTM Platform for Engineered Exosomes and Therapeutic Potential of Codiak’s exoSTING Highlighted at the 2019 American Association for Cancer Research Annual Meeting
4/1/2019
Codiak BioSciences, Inc., a leading exosome therapeutics company, today presented data supporting the therapeutic potential of the engExTM Platform for engineering exosomes and its exoSTING product candidate as highlighted at the 2019 American Association for Cancer Research (AACR) Annual Meeting, held March 31 through April 3 in Atlanta, Georgia.
-
Codiak BioSciences Names Andrea DiFabio Chief Legal Officer
2/20/2019
Codiak BioSciences, Inc., a leading exosome therapeutics company, today announced the appointment of Andrea DiFabio as Chief Legal Officer. Ms. DiFabio will serve on the executive leadership team and report to Codiak’s president and CEO, Douglas E. Williams, Ph.D.
-
Jazz Pharmaceuticals and Codiak BioSciences Announce Strategic Collaboration to Research, Develop and Commercialize Engineered Exosomes to Create Therapies for Hard-to-Treat Cancers
1/3/2019
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Codiak BioSciences, Inc. today announced that the companies have entered into a strategic collaboration agreement focused on the research, development and commercialization of exosome therapeutics to treat cancer.
-
Codiak BioSciences Presents First Data on exoSTING - A Novel Engineered Exosome Therapeutic Targeting Checkpoint Refractory Tumors at the Society for Immunotherapy of Cancer's 33rd Annual Meeting
11/6/2018
Codiak BioSciences, Inc., the leading exosome therapeutics company, today announced results from preclinical studies demonstrating the potential of Codiak's proprietary engineered exosome therapeutic, exoSTING.
-
Codiak BioSciences Names Robert M. Brenner, M.D. Executive Vice President, Research and Development
9/11/2018
Dr. Brenner will serve on the executive leadership team and report to Codiak's president and CEO, Douglas E. Williams, Ph.D.
-
Codiak BioSciences Names Richard Brudnick Chief Business Officer and Head of Strategy
6/4/2018
Codiak BioSciences, Inc announced the appointment of Richard Brudnick as Chief Business Officer and Head of Strategy.
-
Codiak BioSciences Release: Potential Therapeutic Use Of Exosomes Reported In Nature
6/8/2017
-
BioSpace is proud to present its NextGen “Class of 2017,” which is a list of 20 up-and-coming life science companies that launched no earlier than 2014.
-
Codiak BioSciences Names Benny Sorensen, M.D., Ph.D., Vice President And Head Of Clinical Development
10/13/2016
-
Codiak BioSciences Names Jan Lötvall, M.D., Ph.D., Chief Scientist
5/17/2016
-
Former Biogen Exec's Startup Codiak BioSciences Bags Another $61 Million, Totaling $92 Million for Exosome Research
1/26/2016
-
Codiak BioSciences Names First Members Of Executive Team
1/5/2016